Dear Editor, We are grateful to Gurevich and colleagues for their correspondence [1] , highlighting our review of clinical outcomes in male patients with Fabry disease after enzyme replacement therapy (ERT) [2] . This is one of a series of papers published in Molecular Genetics and Metabolism (MGM) or MGM Reports that describe the results of a unique systematic review of the published literature on therapeutic outcomes in patients with Fabry disease, initiated and guided by established experts in this field with extensive experience in patients' clinical care [2] [3] [4] [5] [6] .
We commend the authors for highlighting the importance of standardisation in the design, conduct and reporting of systematic reviews and concur with their comments on the necessity to report on bias in the published literature. The initial series, as submitted to MGM, included a manuscript with the detailed description of the methodology and bias evaluation for all papers. However, MGM's peer review as stand-alone publication resulted in conflicting feedback from reviewers, and this paper has now been published by the European Journal of Medical Genetics [7] .
We confirm that the data search and extraction for this series was conducted in line with recommended practice and that our analysis included a grading of evidence using the levels of evidence classification published by the Oxford Centre for Evidence-Based Medicine [8] . All Grade 1-3 publications were assessed for risk of bias based on the Cochrane tool for assessing bias originally developed for randomised trials [9] . Importantly, pharmaceutical sponsorship of a study was also noted and when insufficient data were available to make a judgement on its impact, the item was noted as a potential risk.
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